Soluble PD-1 and PD-L1: predictive and prognostic significance in cancer

被引:262
|
作者
Zhu, Xinxin [1 ]
Lang, Jinghe [1 ]
机构
[1] Chinese Acad Med Sci, Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Obstet & Gynecol, Beijing, Peoples R China
关键词
soluble; PD-1; PD-L1; tumor immunity; biomarker; CELL LUNG-CANCER; DEATH-LIGAND; PROGRAMMED DEATH-1; ANTITUMOR IMMUNITY; T-CELLS; HEPATOCELLULAR-CARCINOMA; CLINICAL-SIGNIFICANCE; POOR-PROGNOSIS; PD-1/PD-L1; BLOCKADE; CIRCULATING PD-L1;
D O I
10.18632/oncotarget.18311
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The membrane-bound molecules programmed death 1 (PD-1) and its ligand PD-L1 (PD-1/PD-L1) belong to the immune checkpoint pathway. PD-1 pathway downregulates effector T cells in immune response, thereby causing immune suppression. Recent studies have revealed that membrane-bound PD-1 and PD-L1 also have soluble forms. These soluble forms increase the complexity and diversity of the composition and function of the PD-1/PD-L1 signaling pathway. However, the exact roles of these molecules remain unknown. The objective of this systematic review was to elucidate the biological significance of soluble PD-1/PD-L1 in human cancers and evaluate whether they are potential diagnostic, therapeutic, or prognostic biomarkers. We expect to provide new clues for future research on soluble PD-1/PD-L1 pathway in human malignant tumors.
引用
收藏
页码:97671 / 97682
页数:12
相关论文
共 50 条
  • [21] The role of lncRNAs and circRNAs in the PD-1/PD-L1 pathway in cancer immunotherapy
    Jiang, Wenxiao
    Pan, Shuya
    Chen, Xin
    Wang, Zhi-wei
    Zhu, Xueqiong
    MOLECULAR CANCER, 2021, 20 (01)
  • [22] From rough to precise: PD-L1 evaluation for predicting the efficacy of PD-1/PD-L1 blockades
    Zhao, Xuan
    Bao, Yulin
    Meng, Bi
    Xu, Zijian
    Li, Sijin
    Wang, Xu
    Hou, Rui
    Ma, Wen
    Liu, Dan
    Zheng, Junnian
    Shi, Ming
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [23] Expression, prognostic significance and therapeutic implications of PD-L1 in gliomas
    Vimalathas, Gayaththri
    Kristensen, Bjarne Winther
    NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 2022, 48 (01)
  • [24] A snapshot of the PD-1/PD-L1 pathway
    Ghosh, Chinmoy
    Luong, Gary
    Sun, Yue
    JOURNAL OF CANCER, 2021, 12 (09): : 2735 - 2746
  • [25] Predictive biomarkers for PD-1 and PD-L1 immune checkpoint blockade therapy
    Song, Yue
    Li, Zhaoming
    Xue, Weili
    Zhang, Mingzhi
    IMMUNOTHERAPY, 2019, 11 (06) : 515 - 529
  • [26] PD-1/PD-L1 Inhibitors in Cervical Cancer
    Liu, Yuncong
    Wu, Li
    Tong, Ruizhan
    Yang, Feiyue
    Yin, Limei
    Li, Mengqian
    You, Liting
    Xue, Jianxin
    Lu, You
    FRONTIERS IN PHARMACOLOGY, 2019, 10
  • [27] Progress and challenges of predictive biomarkers of anti PD-1/PD-L1 immunotherapy: A systematic review
    Teng, Feifei
    Meng, Xiangjiao
    Kong, Li
    Yu, Jinming
    CANCER LETTERS, 2018, 414 : 166 - 173
  • [28] PD-1/PD-L1 pathway inhibitors in advanced prostate cancer
    Velho, Pedro Isaacsson
    Antonarakis, Emmanuel S.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2018, 11 (05) : 475 - 486
  • [29] PD-1/PD-L1 as a prognostic factor in leukemia
    Hadi Rezaeeyan
    Seyedeh Nafiseh Hassani
    Mojgan Barati
    Mohammad Shahjahani
    Najmaldin Saki
    Journal of Hematopathology, 2017, 10 : 17 - 24
  • [30] Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway
    Ohaegbulam, Kim C.
    Assal, Amer
    Lazar-Molnar, Eszter
    Yao, Yu
    Zang, Xingxing
    TRENDS IN MOLECULAR MEDICINE, 2015, 21 (01) : 24 - 33